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TO THE EDITOR
Recessive dystrophic epidermolysis
bullosa (RDEB) is a mechanobullous
disease caused by mutations in the
COL7A1 gene that encodes type VII
collagen (C7) at the dermal–epidermal
junction (DEJ) (Fine et al., 2008). The
C7 protein is synthesized by both
keratinocytes and fibroblasts (Stanley
et al., 1985). We demonstrated pre-
viously that intradermal injections of
allogeneic fibroblasts in RDEB can
increase C7 expression at the DEJ,
although that study did not disclose
how long the benefits were sustained
for or indicate a therapeutic mode of
action (Wong et al., 2008). Allogeneic
fibroblasts could not be detected 2
weeks after injection but, in some
individuals, there was increased C7
protein at the DEJ for at least 3 months.
To investigate this further, we injected
5106 per cm2 normal control allo-
geneic fibroblasts (ICX-RHY, Vavelta,
Intercytex; Manchester, UK) into one
RDEB subject and took biopsies at days
7, 15, 30, 90, 180, 270, and 360. Each
injection volume was 0.25ml cm2; we
also injected a similar volume of
normal saline to adjacent skin (noting
observations by Venugopal et al. (2010)
that saline can also increase C7 in
RDEB skin) and took biopsies at days
15 and 90. Clinicopathological details
of the subject studied have been pub-
lished previously (case 5; Wong et al.,
2008). This patient is a compound
heterozygote for the COL7A1 muta-
tions c.2044C4T (p.Arg682X) and
IVS87þ 4A4G. This particular donor
splice-site mutation creates a leaky
splice site, which leads to either
in-frame skipping of exon 87 (69-bp)
or wild-type sequence; this also allows
for tracking of the mutant allele in skin
biopsy complementary DNA. We as-
sessed C7 immunolabeling at the DEJ
(as described previously; Wong et al.,
2008), COL7A1 gene expression by
quantitative real-time RT-PCR (using a
primer pair upstream of the splice-site
mutation and another pair spanning the
potential exon skip), and gene expres-
sion profiling using Sentrix Human-6
Whole Genome Expression Beadchips
(Illumina, San Diego, CA); see Supple-
mentary Materials and Methods online
for full details. Quantification of immu-
nofluorescence microscopy intensities
for C7 labeling (see Wong et al.,
2008 for Materials and Methods) is
detailed in Supplementary Table 1
online. C7 labeling increased 15 days
after fibroblast injection and was main-
tained for at least 270 days but returned
to baseline levels by 360 days. For the
saline control, at day 15, we noted a
slight increase in labeling at the DEJ but
a return to baseline by 90 days.
COL7A1 gene expression, using both
sets of primers (Figure 1a and b)
showed that following fibroblast injec-
tion, there was a 420-fold increase at
days 15 and 90, but this returned to
baseline at day 180 and thereafter.
Saline injection also resulted in a
approximately 5-fold increase in patient
skin COL7A1 gene expression at day
15, but levels at day 90 were similar to
baseline (Figure 1a and b). For the
COL7A1 primers spanning the splice-
site mutation, at baseline, the ratio of
wild-type to in-frame exon skip of exon
87 transcripts was approximately 2:3
(Figure 1b): this expression ratio per-
sisted in all biopsy material.
With regard to mechanism, no dif-
ferences were noted in gene expression
for cytokines already known to increase
COL7A1 (full details are shown in
Supplementary Tables 2–10 online). Of
note, however, we observed a 43-fold
increase in expression of the gene for
heparin-binding epidermal growth fac-
tor-like growth factor (HB-EGF) (Iwa-
moto and Mekada, 2000), and
quantitative real-time RT-PCR showed
a similar temporal pattern to the
COL7A1 quantitative real-time RT-
PCR data (linear correlation, r¼0.978;
Po0.0001; compare HB-EGF data in
Figure 1c with COL7A1 expression in
Figure 1a and b). We also noted that
gene expression profiles of FOS (linear
correlation, r¼0.864; Po0.0006) and
JUN (linear correlation, r¼0.945;
Po0.0001) were also highly similar to
the pattern of increased COL7A1 ex-
pression at the different time points
(Supplementary Tables 2–10 online).
JUN and FOS form the AP-1 transcrip-
tion complex, which can bind to the
COL7A1 promoter and enhance gene
expression (Nakano et al., 2001).
To investigate whether the upregula-
tion of HB-EGF might be related to the
increased expression of COL7A1, sub-
confluent-cultured keratinocytes and
fibroblasts, both normal control and
from two subjects with RDEB (this
study individual and an unrelated
subject with the COL7A1 muta-
tions c.1732C4T (p.Arg578X) and
c.7786delG (p.Gly2593fsX4), were
treated with 100 ngml1 recombi-
nant HB-EGF protein (R&D Systems,
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Abingdon, UK) or 10ngml1 TGFb1
(R&D Systems) as positive control
(Calonge et al., 2004). HB-EGF treat-
ment led to upregulation of COL7A1
mRNA in keratinocytes and fibroblasts
in all cells (Figure 2a), as did treatment
with transforming growth factor-b1
(Figure 2b). JUN and FOS expression
levels were also upregulated in all cells
(Figure 2c and d).
This study has shown that a single
fibroblast injection in an individual with
RDEB can lead to increased C7 protein
labeling at the DEJ for B9 months and
increased COL7A1 gene expression
for B3 months, at least some of which
must be due to increased expression of
mutant COL7A1 allele(s). The elevated
COL7A1 expression is paralleled by
increased expression of HB-EGF and,
in vitro, incubation of keratinocytes
and fibroblasts with HB-EGF leads to
increased COL7A1 expression, poten-
tially via increased AP-1 transcription
factor. In vivo, we hypothesize that
allogeneic fibroblasts (and to a much
lesser extent saline) induce subclinical
inflammation, leading to upregulation
of HB-EGF (probably by the reci-
pients’ own keratinocytes, which may
be sustained for several months in an
autocrine manner; Hashimoto et al.,
1994; Goishi et al., 1995). Our study
does not unequivocally define the
source of the new C7 in patient skin
(direct from donor fibroblasts or indir-
ectly from recipient keratinocytes/fibro-
blasts; for related studies, see Ortiz-Urda
et al., 2003; Woodley et al., 2003;
Fritsch et al., 2008; Kern et al., 2009;
Conget et al., 2010; Yan and Murrell,
2010) but it does define a time period for
the cellular benefits of allogeneic fibro-
blasts in RDEB, as well as identifying a
previously unreported role for HB-EGF
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Figure 1. Quantitative real-time RT-PCR (qRT-PCR) reveals increased expression of COL7A1 and heparin-binding epidermal growth factor-like growth
factor (HB-EGF) for at least 90 days following a single injection of allogeneic fibroblasts and a smaller, more transient increase following saline injection.
(a) COL7A1 gene expression using primers designed to amplify exons 54–55 reveals increased expression at 15 days following fibroblast injection (D15), which
is sustained for 90 days (D90) but not 180 days (D180) or thereafter. The day 15 post-saline injection sample (S15) also shows a slight increase in COL7A1
expression but this is not present at 90 days (S90). (b) COL7A1 gene expression using primers designed to amplify exons 86–90 which also allows
for measurement of the recessive dystrophic epidermolysis bullosa patient’s mutant COL7A1 allele (in-frame exon skipping of exon 87), shows a similar profile
of gene expression changes to the upstream amplification in a, with clear evidence of increased expression of the mutant allele. (c) A similar temporal pattern
for expression of HB-EGF is shown in the different biopsy samples following fibroblast or saline injection. Co1, control subject 1; Co2, control subject 2;
D, day; S, saline; numbers refer to days after injection.
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in increasing COL7A1 expression. More-
over, our preliminary observation is of
interest in trying to dissect a potential
‘‘magic bullet’’ from cell therapy for
RDEB, notwithstanding the caveat
that HB-EGF contributes to tumorigeni-
city, and individuals with RDEB are
at greatly increased risk of developing
squamous cell carcinoma (Kivisaari
et al., 2010).
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Figure 2. Keratinocytes and fibroblasts treated with recombinant heparin-binding epidermal growth factor-like growth factor (HB-EGF) or transforming
growth factor-b1 (TGF-b1) show increased expression of COL7A1, JUN, and FOS. (a) COL7A1 expression following HB-EGF; (b) COL7A1 expression
following TGF-b1; (c) JUN expression following HB-EGF; and (d) FOS expression following HB-EGF. The four grouped bars represent different cells types,
control, and recessive dystrophic epidermolysis bullosa (RDEB), as shown in the key.
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TO THE EDITOR
In the October issue of this journal,
De Giorgi et al. (2010) present a novel
morphological approach for the enrich-
ment and visualization of circulating
tumor cells (CTCs) by trapping cells larger
in size than a leukocyte in a filter. The
topic is of great interest as CTCs are
potential precursors of metastases and
their detection is likely to be of prognostic
value in melanoma (Mocellin et al., 2006).
We wish to comment on two aspects
of the article.
First, the authors are wrong in their
statement that in ‘‘cutaneous melanoma
patients CTCs have been studied only by
means of real time RT-PCR’’ (introduction
page 2440). We recently presented an
immunomagnetic approach for the en-
richment and detection of melanoma
chondroitin sulfate proteoglycan (MCSP)-
positive circulating melanoma cells
(Ulmer et al., 2004; Ulmer and Fierlbeck,
2006). We showed that frequencies
of CTCs were stage dependent and
were associated with the tumor load of
the patient. The detection of two or more
CTCs was associated with a reduced
survival in patients with metastatic dis-
ease.
Second, we suggest that any method
used for CTC detection should provide
unambiguous evidence for the malig-
nant nature of the isolated cells. Precise
criteria for defining a cell as CTC
should be applied. CTCs detected by
our immunomagnetic assay had geno-
mic changes typical of malignant mela-
noma. All cells strongly expressed the
MCSP antigen and showed the morpho-
logical criteria for tumor cells (Figure 1).
De Giorgi et al. (2010) used morpho-
logical criteria (nucleo-cytoplasmatic
ratioX50%, hyperchromatic nucleus,
and irregular nuclear shape) in addition
to the size of the cell to define
a cell as CTC. This was supported by
positivity for immunohistochemical
markers (S100, Mart 1 and HMB45)
and tyrosinase messenger RNA as shown
by real-time PCR.
Abbreviations: CTC, circulating tumor cell; MCSP, melanoma chondroitin sulfate proteoglycan;
RT-PCR, reverse transcription-PCR
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